Drugs /

cfi-402411

Back to Drugs List

Overview

Clinical Trials

View Clinical Trials for cfi-402411

Cfi-402411 has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating cfi-402411, 1 is phase 1/phase 2 (1 open).

Deficient DNA Mismatch Repair (dMMR), ER Negative, and ER No Expression are the most frequent biomarker inclusion criteria for cfi-402411 clinical trials.

Anal canal squamous cell carcinoma, breast carcinoma, and cervical carcinoma are the most common diseases being investigated in cfi-402411 clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Cfi-402411
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating cfi-402411 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
cfi402411, cfi 402411

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.